Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer With Urethral Sparing: A Prospective Trial Using an Individualized Approach to Reduce Urinary Toxicity

NCT05804318 is registered in ClinicalTrials.gov with Varian, a Siemens Healthineers Company as lead sponsor.

NCT NCT05804318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05804318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Daily Adaptive Stereotactic Body Radiation Therapy for Prostate Cancer With Urethral Sparing: A Prospective Trial Using an Individualized Approach to Reduce Urinary Toxicity
Lead sponsor
Varian, a Siemens Healthineers Company
Phase
Not applicable
Overall status
Recruiting
Start date
April 13, 2023
Completion date
October 31, 2031
Enrollment
132 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer